Innovative personalized medicine in gastric cancer: time to move forward-Reference-Cited by-同舟云学术

Innovative personalized medicine in gastric cancer: time to move forward

Published:2014-05-10 Issue:1 Volume:86 Page:37-43
ISSN:0009-9163
Container-title:Clinical Genetics
language:en
Short-container-title:Clin Genet

Author:

Lee J.¹,Kim K.-M.²,Kang W.K.¹,Ou S.-H.I.³

Affiliation:

1. Department of Medicine; Division of Hematology-Oncology

2. Department of Pathology; Samsung Medical Center, Sungkyunkwan University School of Medicine; Seoul South Korea

3. Chao Family Comprehensive Cancer Center, Department of Internal Medicine, Division of Hematology-Oncology; University of California Irvine School of Medicine; Orange CA 92868-3298 USA

Publisher

Wiley

Subject

Genetics(clinical),Genetics

Reference58 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

3. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial;Fuchs;Lancet,2014

4. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE);Hansjochen;J Clin Oncol,2014

5. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence;Ou;Crit Rev Oncol Hematol,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer;JCO Precision Oncology;2020-11

2. Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial;Translational Oncology;2019-04

3. Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2–Amplified Gastric Cancer Patient–Derived Cell Model;Translational Oncology;2017-08

4. Correlation between MEK signature and Ras gene alteration in advanced gastric cancer;Oncotarget;2017-05-23

5. A global burden of gastric cancer: the major impact of China;Expert Review of Gastroenterology & Hepatology;2017-04-10